Praxis precision medicines provides corporate update and reports third quarter 2024 financial results

Interim analysis for study 1 of essential3 phase 3 program for ulixacaltamide in essential tremor (et) confirmed for q1 2025; nda filing anticipated in 2025

PRAX Ratings Summary

PRAX Quant Ranking